# Viemed Healthcare, Inc. (VMD)

> Source: Nexqual · https://nexqual.com/VMD · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Viemed Healthcare, Inc. (VMD), nexqual.com/VMD" · informational, not investment advice.

**Price:** USD 9.99 (+3.20% on the day) · last close of Oct 28, 2026; US market pre market, not a live price. Prev close 9.68 · day 9.66–10.01 · 52w 6.05–12.61 · market cap $381M · NCM

## Key facts
- 1 of 80 tracked superinvestors hold VMD (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $347K; 2 not under a Rule 10b5-1 plan ($347K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 12.5 (range 11–14).
- Total return with dividends: 1Y +52.8% vs S&P 500 +13.6%; 5Y +74.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-04, EPS estimate USD 0.12, revenue estimate $80.8M.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold VMD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.1M | Added +1.0% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Frazier William | Chief Medical Officer | 10,000 | $117K | 12% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-24 | Smokoff Timothy | Director | 20,000 | $230K | 20.9% | No | Too little history (no open-market trades in 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 12.5 (low 11, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | Barrington Research | Initiated | Outperform | $14 |
| 2026-08-06 | Freedom Broker | Downgrade | Buy → Hold | $11 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +52.8% | +74.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +53.0% | +11.7% |
| Volatility (annualized) | 39.7% | 41.2% |
| Max drawdown | -30.5% (Jul 2026→Aug 2026) | -49.6% (Apr 2023→Jul 2025) |

## Peers (Medical Devices)
INSP (Inspire Medical Systems, Inc.) USD 70.97 -0.46% · ESTA (Establishment Labs Holdings Inc) USD 68.97 +3.02% · BFLY (Butterfly Network, Inc.) USD 7.81 +5.83% · UFPT (UFP Technologies, Inc.) USD 286 -3.00% · TMDX (TransMedics Group, Inc.) USD 66.9 -4.06% · ALMR (Alamar Biosciences, Inc.) USD 34.3 +7.42%

## More
Full page: https://nexqual.com/VMD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.12 | $0.13 | -5.1% | $80.8M | 3 |
| Next quarter (ends 2026-12-31) | $0.15 | $0.15 | +0.0% | $83.5M | 3 |
| Current fiscal year (ends 2026-12-31) | $0.41 | $0.46 | -9.2% | $317.9M | 3 |
| Next fiscal year (ends 2027-12-31) | $0.54 | $0.61 | -10.9% | $353.6M | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.07 | $0.10 | Miss −30.0% | — |
| — | Quarter ended Mar 31, 2026 | $0.06 | $0.09 | Miss −33.3% | — |
| — | Quarter ended Dec 31, 2025 | $0.14 | $0.13 | Beat +7.7% | — |
| — | Quarter ended Sep 30, 2025 | $0.09 | $0.09 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).